Manufacturing, Biologic Drugs

AGC Biologics Partners with BioConnection to Offer Biopharma Drug Substance and Drug Product Development and Manufacturing

May 25, 2024

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

AstraZeneca Plans $1.5 Billion ADCs Facility in Singapore

May 20, 2024

The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.

Polysorbates: Part(icle) of the Problem?

May 05, 2024

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

Improving ADC Manufacture Means Stricter Containment Requirements and Continuous Advancement of Analytics (INTERPHEX 2024)

April 18, 2024

The improvement of ADC manufacturing now demands increased containment requirements and continually advancing analytical detection of molecules in manufacturing spaces.

WMFTS Showcases New Single-Use Solutions Designed to Optimize Fluid Management

April 16, 2024

WMFTS has launched WMArchitect, a single-use product line that offers ready-to-use single-use assemblies and custom-designed workflows for biopharma fluid management.

Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy

April 05, 2024

Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.

Roche Sells Large-Scale Biologics Manufacturing Site in US to Lonza for $1.2 Billion

March 26, 2024

The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

March 16, 2024

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Review of SUT Adoption in Biopharma Manufacturing

March 16, 2024

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

March 14, 2024

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.